Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053)

F T Aweeka, J G Gambertoglio, C van der Horst, R Raasch, M A Jacobson, F T Aweeka, J G Gambertoglio, C van der Horst, R Raasch, M A Jacobson

Abstract

Foscarnet and zidovudine (ZDV) pharmacokinetic parameters were not altered in five patients receiving 14 days of concomitant therapy. Foscarnet clearance in plasma averaged (+/- standard deviation) 0.16 +/- 0.03 and 0.13 +/- 0.05 liter/h/kg of body weight in the absence and presence of ZDV. ZDV parameters were also not significantly altered, with a mean (+/- standard deviation) oral clearance of 2.7 +/- 1.0 and 2.6 +/- 0.8 liter/h/kg for the 2 study days, respectively.

References

    1. J Infect Dis. 1988 Oct;158(4):862-5
    1. Clin Pharmacokinet. 1989 Jul;17(1):1-9
    1. Am J Med. 1992 Feb 14;92(2A):26S-29S
    1. J Chromatogr. 1990 Jan 26;525(1):133-40
    1. J Chromatogr. 1989 Mar 24;488(2):447-55
    1. Antimicrob Agents Chemother. 1989 Jul;33(7):1023-31
    1. Antimicrob Agents Chemother. 1989 May;33(5):742-5
    1. Clin Pharmacol Ther. 1989 Aug;46(2):190-7
    1. Clin Pharmacol Ther. 1988 Jul;44(1):65-73
    1. Pharm Res. 1992 Feb;9(2):228-35
    1. J Infect Dis. 1991 Jun;163(6):1219-22
    1. AIDS. 1990 Mar;4(3):229-32
    1. Lancet. 1985 Jun 29;1(8444):1480-2
    1. Antimicrob Agents Chemother. 1989 May;33(5):778-80
    1. Antimicrob Agents Chemother. 1989 May;33(5):663-9
    1. Antimicrob Agents Chemother. 1989 May;33(5):736-41
    1. J Chromatogr. 1988 Sep 23;431(1):123-33

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever